Plasma concentration of thymus and activation-regulated chemokine in childhood asthma by Reda, Shereen M et al.




Plasma concentration of thymus and activation-regulated chemokine  
in childhood asthma 
 
INTRODUCTION 
T helper 2 (Th2) lymphocytes play a crucial role in 
the pathogenesis of bronchial asthma1. This subset 
of cells has been functionally identified by the 
production of a profile of cytokines namely IL-4, 
IL-5, IL-9 and IL-132 and by the preferential 
expression of CC chemokine receptor 3 (CCR3), 
CCR4 and CCR8 3.  
     Thymus and activation-regulated chemokine 
(TARC; CCL 17) is the ligand for CCR4 receptor; 
Imai and associates4, in 1996, first described the 
isolation and molecular characterization of TARC 
by cloning the D3A gene from peripheral blood 
mononuclear cells (PBMCs) after stimulation with 
phytohemagglutinin (PHA). This chemokine is 
constitutively expressed in the thymus and is 
produced by monocyte-derived dendritic cells 
(DCs) and endothelial cells. The gene encoding 
TARC is located on chromosome region 16q13 5. 
The gene product is a basic protein with 71 amino 
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Background: Thymus and activation-regulated chemokine (TARC) is 
responsible for trafficking of T helper 2 lymphocytes into sites of allergic 
inflammation. However, its role in assessing the severity of acute asthma in 
children is still unclear. 
Objective: We sought to evaluate plasma TARC as a marker for monitoring 
asthma exacerbation in terms of asthma attack severity.  
Methods: Plasma TARC concentration was estimated in 24 asthmatic children 
aged between 2 and 17 years attending the Pediatric Allergy and Immunology 
Unit of Children’s Hospital, Ain Shams University, and 23 age and sex-
matched healthy children using a sandwich enzyme immunoassay technique. 
For asthmatic patients, the measurement was performed during and after the 
resolution of acute asthma attack. In addition, complete hemogram and 
plasma total IgE were evaluated and peak expiratory flow rate was assessed in 
asthmatic patients during and after acute asthma exacerbation. 
Results:  Plasma TARC mean concentration was significantly higher during 
acute asthma (839.2 ± 453.6 pg/ml) than after resolution of symptoms (416.5 
±324.8 pg/ml) and both were statistically higher than the control value (165.7 
±135.2 pg/ml). During acute attacks of asthma, plasma TARC level was 
significantly elevated among patients with severe attacks of wheezing 
(1336.3±431.2 pg/ml) than in those with moderate (743.8±91.8 pg/ml) and 
mild (437.5±66.1 pg/ml) attacks and inversely related to PEFR measurements 
during attacks (r = -98, P<0.001). Meanwhile, no significant relationship was 
found between plasma TARC levels and either plasma total IgE levels or the 
absolute eosinophil count. Neither the history of other atopic symptoms nor 
family history of atopy influenced plasma TARC levels. A significant reduction 
in plasma TARC level was observed after treatment with inhaled ß2 agonist 
drugs either alone or in conjunction with inhaled glucocorticoids. 
Conclusion: Our findings support the concept that TARC may be implicated in 
the pathogenesis of asthma. Plasma TARC is a useful marker in monitoring the 
severity of asthma exacerbation and in assessing the degree of allergic 
inflammation in the asthmatic airway. This would help physicians to design 
appropriate therapy in terms of dose and duration of treatment especially 
among children with quiescent asthma. Future studies should focus on using 
TARC antagonists as a new approach to asthma immunotherapy. 
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acids and a predicted mass of 8 kd. It acts on the 
chemokine receptor CCR4, which is expressed on 
PBMCs and human T lymphocytes6.  
      In vitro studies showed that TARC could induce 
selective migration of lymphocytes, especially with 
the phenotype of Th2 cells7. The expression of 
CCR4 on Th2 lymphocytes and CCR4- specific 
ligand TARC on airway epithelial cells was 
strongly upregulated in endobronchial biopsy 
specimens from asthmatic patients after allergen 
challenge8,9. In addition, tracking of effector Th 
cells that were transplanted into naïve mice 
revealed that these cells predominantly used the 
CCR4-related pathway to recruit Th2 cells to the 
lung after repeated antigen stimulation10. 
CCR4/TARC interaction is thus important in 
regulating the trafficking of Th2 lymphocytes into 
sites of allergic inflammation. TARC has also been 
implicated in the pathogenesis of hypereosinophilic 
syndrome11,12, allergic rhinitis13 and atopic 
dermatitis14. Elevated levels were found in the 
serum of patients with atopic dermatitis as 
compared with control subjects and patients with 
psoriasis. Furthermore, the serum level of TARC 
has been found to correlate with the severity of 
atopic dermatitis15. 
     The aim of this study was to investigate plasma 
TARC concentrations in children with asthma in 




This case-control study comprised 24 asthmatic 
children (17 boys and 7 girls) aged between 2 and 
17 years (mean ± SD: 7.71± 4.69 years). These 
patients were enrolled from the Pediatric Allergy 
and Immunology Unit of Ain Shams University, 
Children’s Hospital. Of these patients, 12 had mild 
persistent asthma and 12 were suffering from 
moderate persistent asthma according to the global 
initiative for asthma guidelines16. The patients were 
enrolled and evaluated during acute asthmatic 
attacks and followed up until the attack subsided 
clinically and then reevaluated. During asthma 
exacerbation, the severity of the acute attack was 
determined clinically and by measuring the peak 
expiratory flow rate (PEFR) 17 where 6 patients had 
mild attack, 10 had moderate attack and 8 had 
severe attack. The asthma exacerbation was 
triggered by exposure to allergens (food or animal 
allergens) in 15 children, exercise induced in 8 
children and upper respiratory tract infection in one 
child.  Among these patients, 12 had history of 
other atopic manifestations such as nasal or skin 
allergy and 18 patients gave history of allergic 
diseases within the family members. At the time of 
the study, none of patients had acute lower 
respiratory tract infection and none were receiving 
oral glucocorticoids. After obtaining the first blood 
sample, all patients started regular inhalation of ß2 
agonist drugs (salbutamole inhaler; dose: 400-
800µg/day) and inhaled GCCs (beclomethasone 
dipropionate; dose: 200-400µg/day) were 
additionally administered to 10 patients (8 patients 
with severe and 2 patients with moderate attacks).  
In addition, 23 age and sex-matched healthy 
children were enrolled in the study to serve as a 
control group. They were recruited from the Out-
patient Clinic of the Children’s Hospital at Ain 
Shams University while presenting with minor 
complaints. None of these children had a personal 
or family history of allergic diseases. 
Study measurements 
Detailed history was taken for the duration and 
severity of symptoms, drug therapy, and family 
history of atopy. Children with data suggestive of 
any concomitant disease were excluded from the 
study. Patients were subjected to a general clinical 
examination, including weight and height 
measurements. Chest examination for the 
assessment of the severity of wheezing and chest 
tightness was performed on the day of sampling. 
Patients under study underwent a complete 
hemogram, including total and differential 
leukocytic counts (Coulter counter T660, 
Coultronics, France).  
Plasma total IgE concentration 
EDTA-anticoagulated peripheral venous blood was 
collected from patients and control subjects and 
centrifuged within 30 minutes of collection at 3000 
rpm for 10 minutes. Plasma concentration of total 
immunoglobulin (Ig) E was measured by enzyme 
linked immunosorbent assay (Pathozyme IgE, 
Omega Diagnostics Limited, UK) and the value of 
IgE used for data analysis was the percentage from 
the highest normal for age17. 
Plasma TARC concentration 
EDTA plasma samples from the studied subjects 
were stored at –20oC until analysis for TARC 
concentration in batch. We used a 96-well 
polystyrene microplate coated with a murine 
monoclonal antibody (mAb) against human TARC. 
The levels of TARC in plasma were measured in 
duplicate by a sandwich enzyme immunoassay 
technique18 using a commercially available kit 
(Quantikin, R&D System, Minneapolis, USA). The 
sensitivity of the kit in detecting TARC was 7 
pg/ml. The intra-assay and inter-assay coefficients 
of variance for measuring plasma TARC 
concentration were 4.0% and 8.3%, respectively. 
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Plasma TARC was measured twice for each 
asthmatic child (during and after resolution of acute 
asthma attack), and the intervals between the first 
and second samples in all patients ranged from 7 to 
10 days. In the healthy control children, plasma 
TARC was measured only once at enrollment. 
 
Statistical analysis 
Statistica for Windows version 5 (Stat soft, Tulsa, 
OK, USA) was used for all statistical analyses. All 
numeric data were expressed as mean ± standard 
deviation and median values. Non-parametric data 
were analyzed using the Mann-Whitney U-test or 
Wilcoxon rank test for paired data. Correlation 
coefficients and their statistical significance were 
determined with Spearman’s rank correlation test. 
Probability values of less than 0.05 were regarded 
as statistically significant. 
 
RESULTS 
Plasma TARC concentrations were significantly 
higher in asthmatic children than healthy controls. 
The mean concentration during acute asthma (839.2 
± 453.6 pg/ml) and that of the same children after 
resolution of the attack (416.5 ±324.8 pg/ml) were 
statistically higher than the control value (165.7 
±135.2 pg/ml). Also, the difference between plasma 
TARC during and after quiescence of asthma attack 
was statistically significant (table 1). 
 
Plasma TARC concentration in relation to the 
severity of acute asthma attacks 
During acute attacks of asthma, the mean plasma 
TARC level was significantly elevated among 
patients with severe attacks of wheezing 
(1336.3±431.2 pg/ml) than those with moderate 
attacks (743.8±91.8 pg/ml) and patients with mild 
attacks (437.5±66.1 pg/ml). Further, the difference 
between plasma TARC levels in patients with 
moderate attacks and those with mild attacks of 
wheezing was significant (Figure 1). Also, an 
inverse relationship between plasma TARC 
concentrations and PEFR was observed among 
asthmatic children during acute attacks of asthma        
(r = -0.98, p<0.001). 
 
Plasma TARC levels in relation to asthma severity 
grade in remission 
After the resolution of acute asthma symptoms, 
plasma TARC level among patients classified as 
having mild persistent asthma (378.3±387.4 pg/ml) 
was comparable with those of moderate persistent 
asthma (454.6±277.3 pg/ml) and both were 
significantly higher than the control values (165.6 
±135.2 pg/ml). Also, plasma TARC levels did not 
significantly correlate with the PEFR measurements 
during the quiescence of asthma (r = 0.45, p>0.05). 
 
Plasma TARC concentration in relation to history 
of other atopic diseases 
Twelve asthmatic patients enrolled in the study had 
personal history of other atopic disorders (3 patients 
with nasal allergy and 9 patients with skin allergy). 
Although the mean plasma TARC level of these 
patients (970±584.6 pg/ml) tended to be higher than 
that of patients with no history of other atopic 
diseases (708.3±225.8 pg/ml) yet, no statistical 
significant difference was observed between both 
groups. Also, no significant difference in plasma 
TARC concentrations was noted between asthmatic 
children with family history of allergic diseases 
(414.8±344.1 pg/ml) and those with no family 
history of allergic diseases (425±242.4 pg/ml).  
Moreover, no significant correlation between 
plasma concentrations of TARC and total IgE was 
detected either during acute asthma exacerbation or 
after remission of the attack (r = 0.08, p>0.05 and r 
= 0.22, p>0.05 respectively). Peripheral blood 
eosinophil count did not correlate with plasma 
TARC concentration either during acute asthma 
exacerbation or after the resolution of asthma attack 
(r = 0.03, p>0.05 and r = 0.33, p>0.05 respectively).    
 
Plasma TARC concentration in relation to drug 
therapy 
During acute asthma attacks, ten patients were 
treated with ß2 agonists and inhaled glucocorticoids 
(GCCs). Among these patients, the mean plasma 
TARC concentration significantly decreased after 
treatment (352.5±223.5 pg/ml) as compared to the 
corresponding value observed before treatment 
(711±259.3 pg/ml). A similar observation was 
noticed among patients who only received inhaled 
ß2 agonist drugs. These patients showed a 
significantly (p<0.05) lower plasma TARC values 
after treatment (462.1±383 pg/ml) than before 
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Table 1: Plasma TARC in the studied sample. 
Studied children Plasma TARC (pg/ml) Z value 2Bp N Range Median Mean ±SD 
0BAsthmatic children        
During acute attack 24 350- 2000 725 839.2 453.6 5.71* <0.0001 
In remission 24 30- 1500 350 416.5 324.8 3.35* <0.001 4.29† <0.0001 
1BControl group 23 24-450 130 165.7 135.2   
* Versus the control group. 































Acute asthma attack 
 
Figure 1: Plasma TARC levels in relation to 
severity of acute asthma attacks. Written values 
represent the mean ± standard deviation; horizontal 
lines indicate the median values and boxes enclose 
the interquartiles. The ranges are marked as 
maximum and minimum. Mann-Whitney test was 
employed for comparison between groups.  
 



































Figure 2: Mean plasma TARC concentration in 
asthmatic children before and after treatment 
with inhaled steroids and ß2 agonists.   
 
DISCUSSION 
The evidence accumulated to date strongly support 
that TARC plays a dominant role in Th2-type 
disease conditions by recruiting Th2 cells into 
inflammatory sites19. In fact, the role of TARC was 
evident in our results since plasma TARC 
concentrations were significantly increased in 
asthmatic children as compared with the control 
group. This finding is in agreement with that of 
Sekiya and co-workers20 who reported increased 
TARC concentration in both sputum and serum 
samples of asthmatic patients as compared to 
healthy subjects indicating that the elevated levels 
of circulating TARC in asthmatics might be a 
reflection of increased TARC expression at 
inflammatory sites in the asthmatic airway. Indeed, 
previous immuno-histochemical studies have 
demonstrated increased ability of bronchial 
epithelial cells to express and produce TARC at 
both the mRNA and protein levels in asthmatic 
patients as compared to normal subjects21. 
An important aim of this study was to evaluate 
plasma TARC in asthmatic children during and 
after the resolution of an asthma attack. Although 
plasma TARC concentrations significantly 
decreased after the resolution of acute asthma when 
compared to the corresponding value observed 
during the attack yet, they were still significantly 
higher than that of the control group. This finding 
denotes that the airway inflammation is still present 
in patients with seemingly stable condition. Based 
on the fact that the elevated circulating TARC in 
asthmatics may be a reflection of increased TARC 
expression at inflammatory sites in the asthmatic 
airway20, it might be suggested that repeated 
monitoring of plasma TARC levels could help in 
assessing the degree of allergic inflammation in the 
asthmatic airway. This would also enable 
physicians to design the appropriate therapy in 
terms of dose and duration of treatment, especially 
among children with quiescent asthma.  
In support of our results, Leung and associates22 
reported that the circulating TARC concentrations 
among asthmatic children were significantly lower 
during the quiescence of asthma symptoms than in 
asthma exacerbation. However, in their report they 
did not comment on whether that decrease was 
comparable with the control values or not. In 
another study by Leung and co-workers23, the 
Reda et al. 
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plasma TARC levels among patients with stable 
asthma were significantly higher than the control 
subjects.  
Another goal of this study was to evaluate 
whether the level of plasma TARC was influenced 
by the severity of asthma attacks. Our results 
showed that during exacerbation of asthma the 
mean plasma TARC level was significantly higher 
among patients with severe asthma attack (1336.3 
pg/ml) as compared with those with moderate 
asthma (743.8 pg/ml) and patients with mild asthma 
(437.5 pg/ml). Also, plasma TARC showed an 
inverse relationship with PEFR measurements 
during asthma exacerbation. These findings denote 
that TARC production is positively correlated with 
the degree of bronchospasm. In this regard, it might 
be suggested that plasma TARC could be a useful 
inflammatory marker in assessing asthma 
exacerbation. On the other hand, after resolution of 
asthma attacks although the plasma TARC level 
tended to be higher among patients with moderate 
persistent asthma (454.6 pg/ml) than in those with 
mild persistent asthma (378.3 pg/ml) yet, no 
statistical significance was observed between both 
groups. Also, PEFR measurements did not 
significantly correlate with the plasma TARC levels 
during the quiescence of asthma. In fact, other 
studies on asthmatic patients reported conflicting 
results concerning the relationship between plasma 
TARC concentrations and airflow indices, in one 
study, no significant relationship between plasma 
TARC levels and the different degrees of flow 
limitation on FEV1 measurement was reported23 
while in another study an inverse correlation was 
found between plasma TARC levels and PEFR 
during asthma exacerbation22. Perhaps, larger 
studies involving population cohorts will be needed 
to confirm the role of plasma TARC concentration 
in assessing disease severity. 
TARC facilitates Th2 cell recruitment into sites 
of allergic inflammation24. In one study, the nasal 
epithelial cells derived from allergic individuals 
released higher concentrations of TARC than those 
derived from non-allergic subjects13. Also, 
Kakinuma and associates25 found a 10-fold increase 
of serum TARC level in patients with atopic 
dermatitis (AD) when compared with levels in 
healthy adults and patients with psoriasis. The 
average value of serum TARC of adult patients 
with AD was 2338.7 pg/ml in that study, which was 
much higher than the mean value observed in our 
patients with asthma exacerbation (839.2 pg/ml). 
This difference would suggest that AD was 
associated with a much larger end organ of TARC 
production (skin) compared to that associated with 
asthma (lower respiratory tract). Also, a rather 
convincing explanation of the difference between 
the above mentioned report and our TARC values 
rely on the fact that we measured the TARC 
concentration in plasma and not serum samples. 
The difference between plasma and serum TARC 
values was illuminated in the study of Fujisawa and 
co-workers15 who found that the average TARC 
level was 253.2 pg/ml in plasma and 3225.9 in the 
corresponding serum in AD patients. They 
concluded that platelets contain high levels of 
TARC that is released during clotting and thus 
plasma samples contain lower concentrations of 
TARC than serum samples. 
In fact, we were interested in studying the 
concentrations of plasma TARC among asthmatic 
patients who had manifestations of other atopic 
diseases such as allergic rhinitis and/or skin allergy 
and to compare these levels with those of 
asthmatics who had not ever experienced these 
atopic symptoms. Our results showed that the 
average plasma TARC concentration among 
asthmatic children with history of skin and/or nasal 
allergy (970 pg/ml) seemed higher than in those 
with no history of atopic diseases (708.3 pg/ml), 
however, this difference did not reach statistical 
significance. Also, when plasma TARC levels were 
re-evaluated after the resolution of asthma attacks, 
no significant differences were found between these 
two groups of patients. It should be stressed here 
that none of our patients had any symptoms of acute 
nasal or skin allergy during the time of the study. 
They were presenting with asthma manifestations 
only. Therefore, the circulating TARC in our 
patients was mainly influenced by asthma 
exacerbation and not by the presence of other atopic 
symptoms or even family history of atopy, since we 
could not establish any significant difference in 
plasma TARC levels between patients with family 
history of allergic diseases and those without family 
history of atopy.  
Analysis of our data did not reveal any 
significant correlation between plasma TARC 
levels and either plasma total IgE levels or the 
eosinophil number in the peripheral blood.  Unlike 
others who reported a weak but significant 
correlation between plasma total IgE and TARC 
levels in 60 asthmatic children23 and a significant 
correlation between serum TARC levels and 
eosinophil number in the peripheral blood of 45 
patients with AD25. The controversy between our 
data and those of others has led us to suggest that 
the circulating TARC level is a more sensitive 
indicator of asthma exacerbation than plasma total 
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IgE and eosinophil number in the peripheral blood 
of our patients. 
Glucorticoids (GCCs) have long been 
extensively used to treat allergic disorders, with 
remarkable success26. For patients with moderate 
and severe asthma, inhaled GCC now represent the 
first line of medication. Although, not fully proven, 
inhibition of elaboration of chemokines 
fundamental to allergic inflammation may be one of 
the mechanisms by which GCCs exert potent anti-
allergic effects27. Sekiya and associates21 reported 
that treatment with various GCCs resulted in 
attenuation of TARC mRNA expression and 
concomitant loss of the ability to produce TARC 
protein. The airway epithelium is the first cell layer 
to be encountered by inhaled GCCs indicating that 
bronchial epithelial cells are potential targets for 
this drug. Since bronchial epithelium-derived 
TARC potentially contributes to allergic 
inflammation via a paracrine mechanism, the 
beneficial effect of inhaled GCCs in bronchial 
asthma is due, at least in part, to the direct 
inhibitory effect of GCCs on TARC generation by 
the bronchial epithelial cells. Our results support 
this notion since asthmatic patients developed a 
significant reduction in their plasma TARC levels 
after being treated with inhaled GCCs drugs. Also, 
Leung et al23 found that in patients with stable 
asthma, plasma TARC levels were significantly 
lower among patients who received inhaled GCCS 
than steroid-naïve patients. Nevertheless, our results 
showed that asthmatic children who were only 
treated by inhaled and/or oral ß2 agonists also 
developed a significant reduction in their plasma 
TARC levels after treatment. It is unclear whether 
the decrease in plasma TARC levels was due to an 
inhibitory effect of ß2 agonists on TARC 
production or whether that was merely due to the 
resolution of asthma attacks. The effect of inhaled 
ß2 agonists on TARC production by the epithelial 
cells is an intriguing question meriting further 
studies.  
In conclusion, plasma TARC is increased in 
childhood asthma especially during acute attacks 
and correlates positively with the severity of 
attacks. These findings add to the increasing 
evidence that this chemokine may be implicated in 
the pathogenesis of asthma and support the concept 
of using inhibitory antibodies and chemokine 
antagonists that interfere with TARC as a new 
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